Regulatory risk Calloway Labs faced regulatory penalties in 2018 related to False Claims Act and Anti-Kickback violations, indicating heightened compliance scrutiny. This presents an opportunity to position robust compliance auditing, documentation controls, and remediation services to prevent future issues and protect revenue streams.

Strategic backing Post-settlement, Calloway was acquired by Ampersand Capital Partners, suggesting ongoing growth plans and a potential appetite for vendors and services that scale with expansion, including integration projects, analytics, and enterprise software.

Growth potential As one of the fastest growing clinical toxicology labs with mid-sized headcount and revenue in the tens of millions, Calloway may need scalable solutions in high-volume testing, data management, and automation to sustain throughput and accuracy.

Tech usage Calloway employs a modern tech stack with web infrastructure and data integration capabilities, signaling opportunities for cybersecurity hardening, cloud-based data analytics, tagging/measurement, and monitoring services to support secure, compliant operations.

Market fit Serving substance abuse screening and drug therapy compliance, Calloway operates in a regulatory-heavy, healthcare-focused segment. Solutions around chain-of-custody, MRO process optimization, reporting, and payer/network interoperability could address pain points and enable broader market penetration.